Retirement Systems of Alabama Sells 455 Shares of Hologic, Inc. (NASDAQ:HOLX)

Retirement Systems of Alabama reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.1% during the 4th quarter, HoldingsChannel reports. The firm owned 719,009 shares of the medical equipment provider’s stock after selling 455 shares during the period. Retirement Systems of Alabama’s holdings in Hologic were worth $51,833,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of HOLX. Creative Planning grew its stake in Hologic by 2.4% during the 2nd quarter. Creative Planning now owns 21,813 shares of the medical equipment provider’s stock worth $1,620,000 after buying an additional 503 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Hologic in the 2nd quarter valued at about $1,212,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Hologic in the 2nd quarter worth about $100,000. Czech National Bank raised its holdings in Hologic by 6.4% in the 3rd quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider’s stock worth $3,854,000 after purchasing an additional 2,843 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after purchasing an additional 582 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 0.2 %

Shares of HOLX opened at $71.58 on Wednesday. The stock has a fifty day moving average of $73.05 and a two-hundred day moving average of $77.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a market capitalization of $16.16 billion, a PE ratio of 21.50, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98. Hologic, Inc. has a fifty-two week low of $68.61 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm posted $0.89 EPS. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have commented on HOLX shares. Mizuho cut their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Morgan Stanley decreased their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. JPMorgan Chase & Co. increased their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, UBS Group raised their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.